Literature DB >> 17292598

Transcriptional regulation in early B cell development.

Martin Fuxa1, Jane A Skok.   

Abstract

Transcription factors and signalling molecules are important for both lineage commitment and lineage-specific regulation. The B cell specification factor Pax5 plays a dual role in B lineage commitment. Simultaneously, it potentiates and limits lineage choice by activating genes that are required for the B cell program while repressing lineage-inappropriate genes; more than 100 of the latter have now been identified. In this context, repression of the tyrosine kinase Flt3 has been shown to be essential for B lineage commitment. Regulation of antigen receptor recombination constitutes another level at which lineage specificity is determined, and the identification of two factors, E47 and FOXP1, which regulate the activity of the recombinase enzymes in B lineage cells, provides insight into the mechanisms that determine this. New information regarding the control of ordered recombination and allelic exclusion comes from studies of cis-acting elements within the Ig loci.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17292598     DOI: 10.1016/j.coi.2007.02.002

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  19 in total

1.  The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.

Authors:  Ilaria Iacobucci; Annalisa Lonetti; Francesca Paoloni; Cristina Papayannidis; Anna Ferrari; Clelia Tiziana Storlazzi; Marco Vignetti; Daniela Cilloni; Francesca Messa; Viviana Guadagnuolo; Stefania Paolini; Loredana Elia; Monica Messina; Antonella Vitale; Giovanna Meloni; Simona Soverini; Fabrizio Pane; Michele Baccarani; Robin Foà; Giovanni Martinelli
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  Critical role of IRF-5 in regulation of B-cell differentiation.

Authors:  Chunyang Lien; Chee-Mun Fang; David Huso; Ferenc Livak; Runqing Lu; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

3.  Expression of essential B cell development genes in horses with common variable immunodeficiency.

Authors:  R L Tallmadge; K A Such; K C Miller; M B Matychak; M J B Felippe
Journal:  Mol Immunol       Date:  2012-03-30       Impact factor: 4.407

4.  The Downstream Transcriptional Enhancer, Ed, positively regulates mouse Ig kappa gene expression and somatic hypermutation.

Authors:  Yougui Xiang; William T Garrard
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  Dual regulation by the Hunchback gradient in the Drosophila embryo.

Authors:  Dmitri Papatsenko; Michael S Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Divergent roles of RelA and c-Rel in establishing chromosomal loops upon activation of the Igkappa gene.

Authors:  Zhe Liu; Zhenyi Ma; Lance S Terada; William T Garrard
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

7.  Transcription of productive and nonproductive VDJ-recombined alleles after IgH allelic exclusion.

Authors:  Janssen Daly; Steve Licence; Aikaterini Nanou; Geoff Morgan; Inga-Lill Mårtensson
Journal:  EMBO J       Date:  2007-09-06       Impact factor: 11.598

8.  Sox4 is required for the survival of pro-B cells.

Authors:  Baohua Sun; Saradhi Mallampati; Yun Gong; Donghai Wang; Véronique Lefebvre; Xiaoping Sun
Journal:  J Immunol       Date:  2013-01-23       Impact factor: 5.422

Review 9.  Immunoglobulin expression in non-lymphoid lineage and neoplastic cells.

Authors:  Zhengshan Chen; Xiaoyan Qiu; Jiang Gu
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

10.  Enforced expression of the transcriptional coactivator OBF1 impairs B cell differentiation at the earliest stage of development.

Authors:  Alain Bordon; Nabil Bosco; Camille Du Roure; Boris Bartholdy; Hubertus Kohler; Gabriele Matthias; Antonius G Rolink; Patrick Matthias
Journal:  PLoS One       Date:  2008-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.